Automate Your Wheel Strategy on GMAB
With Tiblio's Option Bot, you can configure your own wheel strategy including GMAB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GMAB
- Rev/Share 36.8745
- Book/Share 54.3982
- PB 3.5404
- Debt/Equity 0.0279
- CurrentRatio 6.2162
- ROIC 0.1938
- MktCap 121528914903.9763
- FreeCF/Share 10.8131
- PFCF 18.1965
- PE 15.9985
- Debt/Assets 0.0229
- DivYield 0
- ROE 0.219
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 3
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | GMAB | Guggenheim | Neutral | Buy | -- | $43 | Sept. 23, 2025 |
| Downgrade | GMAB | Bernstein | Market Perform | Underperform | -- | -- | April 1, 2025 |
| Upgrade | GMAB | William Blair | Market Perform | Outperform | -- | -- | March 11, 2025 |
| Upgrade | GMAB | Leerink Partners | Market Perform | Outperform | -- | $27 | Feb. 13, 2025 |
| Initiation | GMAB | Redburn Atlantic | -- | Buy | -- | -- | Oct. 8, 2024 |
| Resumed | GMAB | Morgan Stanley | -- | Equal Weight | -- | $31 | Sept. 4, 2024 |
| Downgrade | GMAB | JP Morgan | Overweight | Neutral | -- | -- | Aug. 20, 2024 |
News
GMAB or TECH: Which Is the Better Value Stock Right Now?
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Genmab A/S Sponsored ADR (GMAB) and Techne (TECH). But which of these two stocks is more attractive to value investors?
Read More
GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Genmab stock surges 21.9% after striking an $8 billion deal to buy Merus, adding a late-stage cancer treatment candidate to its proprietary oncology pipeline.
Read More
What Makes Genmab A/S Sponsored ADR (GMAB) a Strong Momentum Stock: Buy Now?
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Genmab A/S Sponsored ADR (GMAB) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Best Momentum Stock to Buy for October 3rd
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Positive
GFI, GMAB and AEG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 3, 2025.
Read More
New Strong Buy Stocks for October 3rd
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Positive
DORM, AEG, GMAB, SCSC and GFI have been added to the Zacks Rank #1 (Strong Buy) List on October 3rd, 2025.
Read More
Major Shareholder Announcement
Published: September 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; September 23, 2025 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that, as of September 19, 2025, Orbis Investment Management Limited through shares and ADRs, representing shares, controlled the voting rights to 3,230,732 shares in Genmab A/S, which amounts to 5.03% of the share capital and voting rights in Genmab A/S. The major shareholder announcement of Orbis Investment Management Limited is attached to this announcement.
Read More
Genmab: Epkinly's Spectacular Data Is The Antidote To The Darzalex Patent Cliff
Published: September 12, 2025 by: Seeking Alpha
Sentiment: Positive
Genmab A/S is leveraging its royalty-centric model and new ADCs like Epkinly to offset upcoming Darzalex patent expiry risks. Epkinly's strong Phase 3 data in follicular lymphoma positions GMAB for blockbuster potential and validates its co-promotion strategy with AbbVie. Despite a recent rally, GMAB remains undervalued versus peers, with robust profitability, cash flow, and a discounted forward P/E ratio.
Read More
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Published: September 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; September 9, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.
Read More
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Published: September 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; September 09, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 47,532 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others.
Read More
Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference
Published: August 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Media Release COPENHAGEN, Denmark; August 26, 2025 Genmab A/S (Nasdaq: GMAB ) announced today that its Chief Executive Officer Jan Van de Winkel and C hief F inancial O fficer Anthony Pagano will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York City, NY at 7 : 45 A M E D T ( 1 : 45 PM CE S T ) on September 9 , 202 5 . A webcast of the fireside chat will be available on Genmab's website at https://ir.genmab.com/events-presentations.
Read More
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Published: August 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; August 12, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 4,563 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others.
Read More
Wall Street Analysts Believe Genmab (GMAB) Could Rally 33.8%: Here's is How to Trade
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Genmab (GMAB) points to a 33.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Genmab Announces Financial Results for the First Half of 2025
Published: August 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
August 7, 2025 Copenhagen, Denmark; Interim Report for the First Half Ended June 30, 2025 Highlights Epcoritamab a dvancing to earlier lines of therapy with the submission of a sBLA to the FDA for epcoritamab plus R 2 in patients with relapsed or refractory FL Rinatabart sesutecan (Rina-S ® ) continues to progress, demonstrating encouraging antitumor activity in endometrial cancer in data presented at the 2025 ASCO Annual Meeting Data from over 40 abstracts highlighting the depth, breadth and strength of Genmab's comprehensive epcoritamab development program presented at multiple medical conferences Genmab revenue increased 19% compared to the first six …
Read More
GMAB vs. ACAD: Which Stock Is the Better Value Option?
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Genmab A/S Sponsored ADR (GMAB) and Acadia Pharmaceuticals (ACAD). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Genmab (GMAB) Upgraded to Strong Buy: Here's Why
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Genmab (GMAB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Wall Street Analysts See a 39.97% Upside in Genmab (GMAB): Can the Stock Really Move This High?
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Genmab (GMAB) points to a 40% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Completion of Share Buy-back Program
Published: June 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; June 30, 2025 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on June 26, 2025. On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.
Read More
Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One
Published: June 23, 2025 by: Seeking Alpha
Sentiment: Neutral
Genmab A/S is a high-margin, royalty-driven biotech with a robust pipeline and strong partnerships, notably with J&J, AbbVie, and Pfizer. Darzalex remains the key revenue driver, but patent protection and new indications should sustain growth for at least four more years. The company boasts a rock-solid balance sheet, undervalued metrics (low PE, PEG, high FCF yield), and active share buybacks.
Read More
Transactions in Connection with Share Buy-back Program
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; June 23, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.
Read More
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Published: June 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; June 17, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 32,117 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others.
Read More
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Published: June 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; June 17, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.
Read More
Transactions in Connection with Share Buy-back Program
Published: June 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; June 16, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.
Read More
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Published: June 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; June 12, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 3,320 restricted stock units and 3,636 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1.
Read More
Why Genmab Stock Smashed It on Monday
Published: June 02, 2025 by: The Motley Fool
Sentiment: Neutral
On a generally upbeat Monday for the stock market, investors weren't only buying into U.S. companies. Quite a few of them also piled into the American Depositary Receipts (ADRs) of Danish biotech Genmab (GMAB 3.94%), on the back of encouraging news from the laboratory.
Read More
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today new data from cohort B2 of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, TOPO1-inhibitor antibody-drug conjugate (ADC). The study showed that with a median on-study follow-up of 7.7 months, treatment with Rina-S 100 mg/m2 every 3 weeks (Q3W) resulted in a 50.0 percent confirmed objective response rate (ORR), including two complete.
Read More
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Media Release COPENHAGEN, Denmark; June 2, 2025 New data showed that rinatabart sesutecan (Rina-S ® ) 100 mg/m 2 led to a confirmed objective response rate (ORR) of 50.0 percent, including two complete responses (CR), and median duration of response (mDOR) was not reached after a median follow-up of 7.7 months Continued evaluation of single-agent Rina-S 100 mg/m 2 in patients with advanced endometrial cancer (EC) is ongoing in the Phase 2 RAINFOL™-01 trial and will be further evaluated in a planned Phase 3 trial Genmab A/S (Nasdaq: GMAB ) announced today new data from cohort B2 of the Phase …
Read More
Transactions in Connection with Share Buy-back Program
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; June 2, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.
Read More
Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference
Published: May 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Media Release COPENHAGEN, Denmark; May 27, 2025 Genmab A/S (Nasdaq: GMAB ) announced today that its C hief F inancial O fficer Anthony Pagano will participate in a fireside chat at the 4 6 th Goldman Sachs Annual Global Health c are Conference in Miami, Florida at 8:00 A M E D T ( 2:00 PM CE S T ) on June 9 , 202 5 . A webcast of the fireside chat will be available on Genmab's website at https://ir.genmab.com/events-presentations.
Read More
Transactions in Connection with Share Buy-back Program
Published: May 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Announcement COPENHAGEN, Denmark; May 26, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.
Read More
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that it will present new research from its comprehensive development program evaluating its late-stage portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 to June 3 in Chicago, Illinois. The presentations will include the first disclosure of results from a Phase 1/2 trial evaluating rinatabart sesutecan (Rina-S®), an investigational folate receptor-alpha (FRa)-.
Read More
About Genmab A/S (GMAB)
- IPO Date 2009-06-01
- Website https://www.genmab.com
- Industry Biotechnology
- CEO Jan G.J. van de Winkel
- Employees 2638